The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
Cerebrolysin is the most clinically tested compound in this book and the most evidence-contested. Five decades of data have not produced scientific consensus. Understanding why requires understanding the commercial provenance of that data.
The central tension resolved: Cerebrolysin has been studied in more human clinical trials than any other compound in this book. It is approved in over 40 countries. It appears in European neurology guidelines. Its mechanistic rationale — neurotrophic factor mimicry via BDNF, NGF, GDNF, and CNTF-homologous peptide fragments — is biologically coherent and supported by extensive preclinical evidence. And: the Cochrane systematic review — the gold standard of independent evidence assessment — has rated the evidence as 'low to very low certainty' across all its updates. The largest independent RCT (CASTA, n=1,070) failed its primary endpoint. A journal editorial titled 'Hope Dies Last' summarized the clinical neurology community's frustration with decades of inconsistent results. The pattern in the literature — positive trials concentrated among industry-affiliated researchers, negative results from independent investigators — is the most important interpretive context and the most underappreciated fact in community discourse about Cerebrolysin.
The community uses Cerebrolysin primarily for an indication (cognitive enhancement in healthy neurologically normal adults) for which there is no clinical trial evidence at all. Every positive trial enrolled patients with acute stroke, TBI, or dementia. The extrapolation from 'it helps injured or demented brains recover' to 'it enhances healthy brain performance' may be biologically reasonable but it is clinically unvalidated. The route issue compounds this: clinical trials used 30 mL IV infusion; the community uses 1-5 mL SubQ or IM. Whether community-equivalent doses by community-equivalent routes produce pharmacologically meaningful exposure is unknown.
The argument for Cerebrolysin: there is more human data than for many compounds in this book. The compound has been used clinically for five decades without a serious safety signal. Community experience is largely consistent with the positive trial findings — subjectively reported cognitive improvement during and after a course. Some positive independent replication does exist at the individual trial level even if Cochrane finds the aggregate uncertain. The compound is a pharmaceutical-grade product (when sourced from EVER Neuro Pharma) with GMP manufacturing quality. The neurotrophic factor mechanism is compelling biologically.
The argument for caution: the positive trial data is commercially concentrated. The independent evidence is negative (CASTA) or insufficient (Cochrane). The community uses it at doses, by routes, and for indications that have no validated evidence. The composition is incompletely characterized. Sourcing from research vendors rather than pharmaceutical-grade imports removes the quality assurance that distinguishes the clinical trial product from the research chemical market.
Cerebrolysin has been in clinical use since the 1970s. That is longer than most of the compounds in this book have been discovered. In five decades, it has accumulated dozens of randomized controlled trials, multiple meta-analyses, and regulatory approval in over 40 countries. It has also accumulated persistent controversy, Cochrane-level skepticism, and the most concentrated commercial provenance problem of any chapter in this book.
The compound was developed in Austria by what is now EVER Neuro Pharma — a company whose founding identity and ongoing revenue is substantially built around Cerebrolysin. The basic concept predates modern biotechnology: hydrolysis of porcine brain tissue using enzymatic processes produces a mixture of low-molecular-weight peptides and free amino acids. The hypothesis, developed in the 1970s and refined over subsequent decades, was that these fragments would mimic the activity of endogenous neurotrophic factors — the growth factors that support neuronal survival, synaptic plasticity, and brain repair. BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), GDNF (glial cell line-derived neurotrophic factor), and CNTF (ciliary neurotrophic factor) are the primary neurotrophic factors cited in the Cerebrolysin mechanism literature.
The compound became widely used in Eastern Europe, Russia, and increasingly in Asia — most prominently China — through the 1980s and 1990s. In these markets, Cerebrolysin developed a clinical reputation as a neuroprotective and neurorestorative agent. The clinical community's favorable impression, combined with the manufacturer's investment in clinical trials, produced a literature that grew to encompass dozens of RCTs across stroke, traumatic brain injury, Alzheimer's disease, and vascular dementia. By the 2000s, Cerebrolysin was one of the most extensively trialed neuroprotective interventions in the world.
The Western scientific community's engagement with this literature was complicated from the beginning by the provenance of the trials. A review of the authorship of positive Cerebrolysin RCTs reveals a consistent pattern: researchers with financial relationships to EVER Neuro Pharma, often conducting trials at institutions with EVER Neuro Pharma funding. The exception was the CASTA trial — the Cerebrolysin Acute Stroke Treatment in Asia study — which was independently conducted and funded through research grants rather than direct EVER Neuro Pharma industry-sponsored design. CASTA enrolled 1,070 patients, making it the largest Cerebrolysin stroke trial ever conducted. In 2012, CASTA published its results in Stroke. The primary endpoint — a combined global directional test of NIHSS, modified Rankin Scale, and Barthel Index at day 90 — was not statistically significantly different from placebo. The editorial accompanying the CASTA results was titled: 'Hope Dies Last — Evidence Again Fails to Support a Neuroprotectant.'
The Cochrane Collaboration has reviewed the Cerebrolysin evidence multiple times over the decades — for acute ischemic stroke specifically. The 2023 Cochrane review (Ziganshina [3] et al.) is the most current and comprehensive. Its conclusion: the certainty of evidence is low to very low. The review found that the positive signals in the literature are predominantly in industry-affiliated trials and that the evidence base does not meet the threshold for clinical confidence in routine recommendation. CASTA's failure remains the dominant independent data point in the stroke literature.
Against this backdrop, Cerebrolysin entered the biohacking and nootropic community as a premium neuroprotective compound — used not for stroke or TBI (the only contexts where clinical trials exist) but for cognitive enhancement in healthy adults, neuroplasticity support, and general neuroprotection. This is an entirely extrapolated application for which no clinical trial evidence exists. The community uses it at doses far below clinical trial doses, by subcutaneous or intramuscular injection rather than the IV infusion used in every clinical trial, and for an indication (cognitive enhancement in healthy people) that has never been studied.
THE CENTRAL TENSION
Cerebrolysin has more clinical trial data than nearly anything else in this book. It is approved in over 40 countries. It is included in European neurology guidelines. And: the Cochrane systematic review calls the evidence 'low to very low certainty.' The largest independent RCT failed its primary endpoint. Essentially every major positive trial has EVER Neuro Pharma authorship or funding. The community uses it at lower doses than clinical trials, by a different route, for an indication (cognitive enhancement in healthy adults) that has never been studied. All three of these facts — the extensive trial data, the Cochrane skepticism, and the community misapplication — must be held simultaneously to understand what Cerebrolysin actually is and what using it actually means.
Cerebrolysin's gene expression effects are mediated through its proposed neurotrophic factor mimicry. BDNF-pathway activation drives expression of CREB (cAMP response element binding protein) — the transcription factor central to long-term memory consolidation, synaptic plasticity, and neuronal survival. ERK1/2 and PI3K/Akt pathway activation downstream of TrkB drives anti-apoptotic gene expression (Bcl-2 upregulation, Bax downregulation) and synaptic protein synthesis (Arc, PSD-95, GluR1). The neuroinflammation modulation (M1→M2 microglial shift) drives expression changes in inflammatory cytokine genes — reduced IL-1β, TNF-α, and IL-6 alongside upregulated IL-10 and TGF-β. In Alzheimer's animal models, amyloid precursor protein processing gene expression changes suggest reduced amyloidogenic pathway activity. The transcriptional effects documented in preclinical models are consistent with the neurotrophic mechanism. Whether the same transcriptional changes occur in human neurons after IV Cerebrolysin administration has not been directly characterized through gene expression profiling in human tissue — the clinical evidence is based on functional and cognitive outcomes, not direct transcriptomics.
Understanding Cerebrolysin requires abandoning the single-compound framework that applies to every other chapter in this book. There is no molecular weight to look up, no amino acid sequence to verify, no mass spectrometry confirmation that gives you a single number. Cerebrolysin is a mixture.
Cerebrolysin is manufactured by enzymatic hydrolysis of porcine brain cortex proteins. The resulting mixture is filtered and concentrated to produce an injectable solution typically standardized to contain approximately 215.2 mg/mL of protein hydrolysate. EVER Neuro Pharma specifies the composition as approximately: 25% low-molecular-weight peptides (MW < 10,000 Da; most fragments below 1,000-3,000 Da) and 75% free amino acids and small amino acid derivatives. The specific peptide identity and relative concentration of individual fragments has not been fully publicly characterized. Published analyses have identified fragments with sequence homology to BDNF, NGF, GDNF, CNTF, IGF-1, and multiple other growth factor peptides — but the complete peptide map of any given batch has not been published to the scientific community's satisfaction.
THE COMPOSITION PROBLEM — WHAT IT MEANS FOR THE EVIDENCE BASE
In pharmaceutical science, a compound's identity and purity are prerequisites for meaningful clinical trials. You must know what you are testing. For Cerebrolysin: (1) the peptide content is a biological mixture from animal brain tissue, meaning batch-to-batch variation is inherent; (2) the complete peptide map is not publicly available; (3) independent manufacturers cannot produce an identical product for comparison studies; (4) when a trial shows a positive effect 'from Cerebrolysin,' it is not possible to attribute that effect to any specific peptide or peptide class within the mixture. This does not make clinical trials of Cerebrolysin meaningless — we can study whether the mixture produces a clinical effect. But it creates an interpretive challenge that does not exist for single-compound drugs, and it makes the evidence less conclusive than equivalent-size trials of chemically defined drugs would be.
Based on published analyses and the manufacturer's claims, the proposed biologically active fractions include: BDNF-homologous fragments (proposed mechanism: TrkB receptor activation → neuronal survival and synaptic plasticity); NGF-homologous fragments (proposed: TrkA activation → cholinergic neuron support, particularly relevant for Alzheimer's disease); CNTF-like fragments (proposed: LIFR/gp130 complex activation → motor neuron support); IGF-1-like fragments (proposed: IGF-1 receptor activation → neuronal growth and anti-apoptotic signaling); and fragments with opioid peptide activity (proposed: pain modulation and neuroprotection). The complete functional characterization of Cerebrolysin's components as receptor agonists at their respective neurotrophin receptors has not been rigorously established — the evidence for mechanism is predominantly in vitro and animal model, with some upregulation of endogenous BDNF observed in clinical contexts.
Cerebrolysin is available as a sterile injectable solution (1 mL, 2 mL, 5 mL, 10 mL ampoules at 215.2 mg/mL concentration). It is clear to slightly yellow in color. Storage: refrigerate at 2-8°C; do not freeze; protect from light. Shelf life: typically 3 years sealed. Once opened, use immediately — do not store opened ampoules. The parenteral form is the only pharmacologically validated form. The product is manufactured under pharmaceutical GMP standards in Austria — the quality standard for the injectable form sold by EVER Neuro Pharma is pharmaceutical grade, which distinguishes it from compounds sourced from research chemical vendors. Community members who source Cerebrolysin from Russian, Chinese, or Eastern European pharmacies are typically receiving pharmaceutical-grade product. Community members who source from research peptide vendors are receiving a product not manufactured under the same standards.
The peptides in Cerebrolysin are degraded by gastrointestinal enzymes within minutes of oral administration. The GI tract is a peptide-hostile environment — exactly the environment that every injectable peptide in this book bypasses by using SubQ or IV routes. Oral Cerebrolysin produces minimal to no systemic bioavailability of the peptide fractions. Free amino acids are absorbed orally but produce no pharmacological effect beyond basic nutritional contribution. The sublingual route is better than oral but still subjects the peptide fragments to salivary enzymatic degradation and GI degradation of swallowed fractions. Community members using Cerebrolysin orally are not receiving the compound in a pharmacologically meaningful way. This is not controversial — it is basic peptide pharmacokinetics.
The mechanistic case for Cerebrolysin is biologically compelling in principle. Neurotrophic factors — BDNF, NGF, GDNF, CNTF — are well-established mediators of neuronal survival, synaptic plasticity, and brain repair. A compound that mimics their activity would be a powerful neuroprotective and neurorestorative intervention. The question is whether Cerebrolysin's peptide fragments actually achieve this mimicry in a clinically meaningful way.
BDNF is the most well-studied neurotrophic factor in the context of cognition, learning, and neural repair. It binds TrkB receptors on neurons, activating PI3K/Akt (survival), MAPK/ERK (differentiation and synaptic plasticity), and PLCγ (calcium signaling and LTP) pathways. BDNF declines with age, stress, and neurological injury — its restoration is associated with improved neurological outcomes. Cerebrolysin has been shown to: upregulate endogenous BDNF expression in neural tissue (in vitro, animal models); contain peptide fragments with structural homology to BDNF; and produce downstream effects consistent with TrkB activation in preclinical models. A 2024 in vitro study (Cureus) found BDNF upregulation in affected neural cells treated with Cerebrolysin alongside citicoline. Grade B-C: preclinical evidence consistent; in vitro confirmation recent and independent; direct TrkB binding affinity of Cerebrolysin fragments not rigorously characterized.
NGF activates TrkA receptors on cholinergic neurons — particularly relevant for Alzheimer's disease where cholinergic neuron loss is a primary pathological feature. Cerebrolysin contains NGF-homologous fragments and has been shown to upregulate NGF expression in animal models. The cholinergic neuroprotection hypothesis is a primary mechanistic rationale for Cerebrolysin's proposed Alzheimer's application. Grade B-C: preclinical; animal model upregulation documented; direct TrkA binding not rigorously characterized.
Multiple preclinical studies show Cerebrolysin reduces apoptosis in neurons under ischemic, excitotoxic, and oxidative stress conditions — through downregulation of Caspase-3 activity, upregulation of Bcl-2, and reduction of cytochrome c release. The anti-apoptotic effects are the most consistently replicated cellular finding across independent preclinical studies. This provides the mechanistic basis for the stroke and TBI applications — acute injury creates massive neuronal apoptosis; a compound that reduces this apoptotic burden should improve outcomes. Grade B: multiple independent preclinical studies; cellular mechanism plausible; translation to human benefit is the gap.
Following stroke or TBI, microglial activation drives a neuroinflammatory cascade (M1 phenotype) that extends tissue injury beyond the initial insult. Cerebrolysin has been shown in preclinical and some clinical immune biomarker studies to promote M1→M2 microglial shift — reducing the pro-inflammatory phenotype and supporting the tissue-repair, anti-inflammatory M2 phenotype. This mechanism is relevant to both the acute injury applications and the Alzheimer's applications (where neuroinflammation is a key pathological driver). Grade B-C: animal model evidence; some clinical biomarker signals; not definitively characterized.
Cerebrolysin has been shown in Alzheimer's animal models to reduce amyloid-beta plaque burden and tau hyperphosphorylation — two primary pathological hallmarks of AD. These effects are proposed to operate through multiple mechanisms including enhancement of amyloid clearance pathways, reduction of β-secretase activity, and BDNF/NGF-mediated neuronal stabilization. Grade C: animal model; consistent with mechanism; direct human amyloid/tau biomarker effects not confirmed in large RCTs.
For any neurologically active compound, blood-brain barrier penetration is the key pharmacokinetic question. Cerebrolysin's low-molecular-weight peptide fragments (<3,000 Da) are proposed to cross the BBB through several mechanisms: transcytosis via adsorptive mechanisms, passage through temporarily disrupted BBB (particularly relevant in acute stroke/TBI where the BBB is already disrupted), and direct transport via amino acid transporter systems for the free amino acid fraction. The BBB penetration of the intact Cerebrolysin peptide mixture has not been directly characterized in humans. It is pharmacokinetically plausible for some fractions; complete characterization is a significant gap in the evidence base.
This section is the most important in the chapter. The evidence base for Cerebrolysin is large, complex, and divided along commercial provenance lines in a way that requires explicit documentation. The trials that show positive results and the trials that show null or negative results are not a random mix — they are patterned.
READ THIS BEFORE EVALUATING ANY CEREBROLYSIN TRIAL
A systematic review of authorship and funding declarations across the major Cerebrolysin trials reveals a consistent pattern that constitutes the most concentrated commercial provenance problem in this book. Positive trials: predominantly involve investigators who are employees of EVER Neuro Pharma, recipients of EVER Neuro Pharma grants, or who serve on EVER Neuro Pharma advisory boards. The CARS-1, CARS-2, CARS meta-analysis, and multiple Alzheimer's/dementia trials include EVER Neuro Pharma employees as co-authors. Independent trials (no EVER Neuro Pharma funding or authorship): predominantly show null or negative results. CASTA — the largest independent trial (n=1,070) — failed its primary endpoint. This is not merely a 'conflict of interest disclosure' situation — the divide between industry-sponsored and independent trials is the primary driver of the inconsistency in the Cerebrolysin literature. The Cochrane reviewers identified this pattern as a central reason for their 'low to very low certainty' rating. Reading any Cerebrolysin trial without first checking the funding declarations is reading without the most important interpretive context.
CASTA trial (Heiss, Brainin, Bornstein et al., Stroke, 2012) [1]: n=1,070 patients, acute ischemic stroke within 12 hours of onset, 30 mL Cerebrolysin IV daily for 10 days vs placebo + aspirin. Primary endpoint: combined global directional test of mRS, Barthel Index, NIHSS at day 90. RESULT: not statistically significantly different from placebo. Post-hoc subgroup of severe strokes (NIHSS ≥12 at baseline) showed favorable mortality signal (10.5% vs 20.2%) — a hypothesis-generating finding, not a primary result. Overall: the largest independent Cerebrolysin stroke trial is negative on its primary endpoint. Grade A for the trial result; this finding deserves primary weighting in the evidence assessment.
2025 meta-analysis (Patel et al., Cureus, August 2025) [2]: 14 RCTs, n=2,884 patients, acute ischemic stroke. Primary outcome: NIHSS change from baseline. Pooled finding: Cerebrolysin significantly improved NIHSS (mean difference +1.39; 95% CI 0.53-2.25; p=0.020). Secondary outcome functional independence (mRS 0-2): non-significant trend (RR 1.31; 95% CI 0.90-1.91; p>0.05). GRADE certainty: low. This meta-analysis included predominantly industry-associated trials. The NIHSS improvement of 1.39 points, while statistically significant in the pooled analysis, may not reach clinical significance thresholds (typically 3-4 points for stroke trials). The non-significant functional independence finding is the most patient-relevant outcome.
Cochrane review 2023 (Ziganshina et al.): Assessed the complete Cerebrolysin acute ischemic stroke evidence base. Conclusion: evidence certainty is 'low to very low.' Finding: available evidence does not establish clear benefit on outcomes that matter most to patients — functional independence, survival, and quality of life. The Cochrane review is the most methodologically rigorous assessment of this literature and represents the independent scientific consensus.
European Academy of Neurology (EAN) guideline 2021 [6]: Cerebrolysin is referenced as a weak recommendation for pharmacological support in early motor rehabilitation after acute ischemic stroke — based on the available trial data despite its limitations. This guideline reference reflects the regulatory reality that in some European settings, Cerebrolysin remains a clinical option, not a validated recommendation with strong evidence.
Multiple RCTs have studied Cerebrolysin in moderate to severe TBI. The CAPTAIN trials (Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery) have evaluated Cerebrolysin in TBI across Asian patient populations. The trial investigators include EVER Neuro Pharma-affiliated researchers. Results have shown improvements in some cognitive and neurological outcome scales in the Cerebrolysin groups vs placebo. A systematic review (Lucena et al., 2020) of six TBI RCTs found favorable effects on short-term neurological recovery but noted high risk of bias across studies, again linked to industry sponsorship. The TBI evidence, like stroke, shows a pattern of positive industry-sponsored trials with limited independent confirmation. Grade B for TBI neuroprotection — genuine signal in the literature but concentrated provenance substantially reduces confidence.
Multiple RCTs have evaluated Cerebrolysin in Alzheimer's disease and vascular dementia, primarily measuring cognitive outcome scales including ADAS-Cog, MMSE, and CGI. One frequently cited finding: Cerebrolysin produced a 3.8-point improvement in ADAS-Cog versus 0.6 points for placebo in vascular dementia trials (Guekht et al.) — described as comparable to the effect size of approved acetylcholinesterase inhibitors. The Gauthier meta-analysis of Alzheimer's trials showed pooled cognitive benefits. EVER Neuro Pharma sponsorship is prominent throughout this literature. The Cochrane vascular dementia review rated the overall evidence quality as 'very low' due to 'imprecision, indirectness, and serious risk of bias.' A 2024 preclinical study in a CADASIL mouse model found Cerebrolysin improved spatial memory and reduced epigenetic aging markers — but did not affect characteristic white matter damage. Grade B for modest cognitive improvements in demented populations; Grade C-D for clinical confidence given provenance concentration.
NO CLINICAL TRIAL EVIDENCE FOR HEALTHY ADULT COGNITIVE ENHANCEMENT
The community's primary use of Cerebrolysin is cognitive enhancement and neuroplasticity support in neurologically healthy adults. There is no randomized controlled trial of Cerebrolysin in neurologically healthy adults for any cognitive endpoint. Zero. Every positive Cerebrolysin RCT enrolled patients with documented neurological pathology — acute stroke, TBI, Alzheimer's disease, or vascular dementia. The biological argument for why the neurotrophic factor mimicry mechanism might produce cognitive benefit in healthy adults is coherent. The clinical evidence for it does not exist. Community users claiming evidence-based support for healthy adult nootropic use of Cerebrolysin are borrowing evidence from an entirely different clinical population. This does not mean Cerebrolysin produces no effect in healthy adults — it means that claim is clinically unvalidated.
Application
Trial Evidence
Grade
Key Finding
Independence / Provenance
Acute ischemic stroke
CASTA (n=1,070, RCT), multiple smaller RCTs, 14-RCT meta-analysis (n=2,884)
B (individual trials); Cochrane: Low
CASTA: primary endpoint FAILED. 14-RCT meta-analysis: NIHSS improvement +1.39 (significant); functional independence: non-significant. Cochrane 2023: low certainty.
CASTA: independent (negative). Smaller trials and meta-analyses: predominantly EVER Neuro Pharma affiliated.
Stroke rehabilitation
CARS-1, CARS-2, CARS meta-analysis
B
Motor function improvement (ARAT scores); positive in both trials
EVER Neuro Pharma employees as co-authors; Dafin Muresanu coordinating investigator received EVER Neuro Pharma grants
Traumatic brain injury
CAPTAIN trials + multiple smaller RCTs
B
Short-term neurological and cognitive improvements vs placebo
EVER Neuro Pharma affiliated; risk of bias: high per systematic review
Alzheimer's disease
Multiple RCTs; Gauthier meta-analysis
B-C
Modest ADAS-Cog improvements (effect size comparable to AChEI)
Predominantly industry affiliated; Cochrane: very low certainty
Vascular dementia
Multiple RCTs including Guekht et al.
B-C
3.8-point ADAS-Cog improvement vs 0.6 placebo
Industry affiliated; Cochrane vascular dementia: very low certainty
Healthy adult cognition
None
X
No RCT exists in neurologically healthy adults
N/A — the evidence does not exist
SubQ/IM vs IV route equivalence
None
X
The clinical trials all used IV; community uses SubQ/IM; no comparison study exists
N/A — untested assumption
| Application | Evidence level | Grade | Confidence | Key limitation |
|---|---|---|---|---|
| Acute ischemic stroke | CASTA (n=1,070, RCT), multiple smaller RCTs, 14-RCT meta-analysis (n=2,884) | B (individual trials); Cochrane: Low | CASTA: primary endpoint FAILED. 14-RCT meta-analysis: NIHSS improvement +1.39 (significant); functional independence: non-significant. Cochrane 2023: low certainty. | CASTA: independent (negative). Smaller trials and meta-analyses: predominantly EVER Neuro Pharma affiliated. |
| Stroke rehabilitation | CARS-1, CARS-2, CARS meta-analysis | B | Motor function improvement (ARAT scores); positive in both trials | EVER Neuro Pharma employees as co-authors; Dafin Muresanu coordinating investigator received EVER Neuro Pharma grants |
| Traumatic brain injury | CAPTAIN trials + multiple smaller RCTs | B | Short-term neurological and cognitive improvements vs placebo | EVER Neuro Pharma affiliated; risk of bias: high per systematic review |
| Alzheimer's disease | Multiple RCTs; Gauthier meta-analysis | B-C | Modest ADAS-Cog improvements (effect size comparable to AChEI) | Predominantly industry affiliated; Cochrane: very low certainty |
| Vascular dementia | Multiple RCTs including Guekht et al. | B-C | 3.8-point ADAS-Cog improvement vs 0.6 placebo | Industry affiliated; Cochrane vascular dementia: very low certainty |
| Healthy adult cognition | None | X | No RCT exists in neurologically healthy adults | N/A — the evidence does not exist |
| SubQ/IM vs IV route equivalence | None | X | The clinical trials all used IV; community uses SubQ/IM; no comparison study exists | N/A — untested assumption |
THE ROUTE AND DOSE GAP — THE MOST IMPORTANT PRACTICAL ISSUE
Clinical trials: 30-50 mL IV infusion daily for 10-20 consecutive days. Community use: 1-5 mL SubQ or IM injection daily for 10-20 days. The difference: (1) Volume — 30 mL IV delivers approximately 6.5 grams of peptide/amino acid mixture; 5 mL SubQ delivers approximately 1.1 grams. (2) Route — IV infusion delivers the compound directly to systemic circulation; SubQ injection relies on local absorption with first-pass tissue processing. (3) Clinical validation — the IV route and 30-50 mL dose are what was studied. The SubQ/IM route at community volumes has not been compared to IV in any bioavailability study. Whether community protocols produce pharmacologically comparable systemic and CNS exposure to clinical trial protocols is an untested assumption. This gap is important: the clinical evidence, whatever its limitations, was produced at doses and routes that the community is not replicating.
Indication
Volume
Route
Duration
Frequency
Acute ischemic stroke
30 mL (6.45 g)
IV infusion over 60-90 min
10 days
Daily
TBI (CAPTAIN trials)
30-50 mL
IV infusion
10-30 days
Daily
Alzheimer's/dementia
10-30 mL
IV infusion
4-6 weeks
Daily; some protocols 5 days/week
Stroke rehabilitation
10-30 mL
IV infusion
21-28 days
Daily; 5 days/week in some protocols
The community has developed protocols by analogy to the clinical trial durations, scaled down for practical and cost reasons. Most community users do not have access to IV infusion infrastructure and use SubQ or IM injection. Typical community protocols:
Protocol
Volume (per injection)
Route
Duration
Notes
Conservative / entry
1 mL (215 mg)
SubQ or IM
10 consecutive days
Lowest community dose; below all clinical trial doses
Standard community
2-5 mL (430-1,075 mg)
SubQ or IM
10-20 consecutive days
Most common; still below 30 mL clinical trial dose
IV-adjacent (some clinics)
10-30 mL
Slow IV push or infusion
10-20 days
Some integrative medicine clinics; closest to clinical trial protocol
SubQ injection: abdomen, outer thigh, or upper arm; 25-27 gauge needle; slow injection (Cerebrolysin is mildly irritating at the injection site if delivered too rapidly). IM injection: vastus lateralis or deltoid; 23-25 gauge needle; may reduce local site irritation vs SubQ at higher volumes. IV use at home: not recommended without clinical training and appropriate catheter infrastructure. Some Eastern European practitioners and some integrative medicine clinics administer 10-30 mL IV in clinic settings — this is closer to the evidence base. Cerebrolysin injectable solution should NOT be frozen, not mixed with other medications in the same syringe, and used from a freshly opened ampoule.
Pharmaceutical-grade Cerebrolysin: the EVER Neuro Pharma product (Austria) is GMP pharmaceutical-grade and is what was used in all the clinical trials. It is widely available at pharmacies in Eastern Europe (Russia, Ukraine, Romania, Bulgaria), China, South Korea, and other approved markets. Community members in the US and Western Europe obtain it through international pharmacy importation — legal gray area for personal use, illegal for resale. Research chemical vendor Cerebrolysin: some research peptide vendors sell 'Cerebrolysin' or 'Cerebrolysin peptides' — these products are not manufactured under pharmaceutical GMP standards and are not the same product used in clinical trials. The quality, safety, and identity of these products is not verified by independent testing. The EVER Neuro Pharma pharmaceutical product is meaningfully different from research vendor alternatives.
Cerebrolysin's safety has been assessed across its large clinical trial database, giving it one of the better-characterized safety profiles for any compound in this book — for its clinical applications at clinical doses. The overall safety signal is favorable: no evidence of organ toxicity, carcinogenicity, or immunotoxicity in the clinical literature. The most common adverse effects are mild and related to the injection route and local tolerability.
Cerebrolysin is derived from porcine (pig) brain tissue. This has two practical implications: (1) Individuals with documented pork allergy should not use Cerebrolysin — the risk of allergic reaction from porcine-derived proteins is a documented concern; (2) Individuals for whom pork-derived products are prohibited by religious practice (including some observant Jewish and Muslim individuals) should be aware of the porcine origin. These are not widely discussed in community discourse.
Pharmaceutical-grade Cerebrolysin (EVER Neuro Pharma) is an approved prescription pharmaceutical in over 40 countries. In the US: not FDA approved; not available as a licensed pharmaceutical; importation for personal use is legally gray; research chemical vendor products are not regulated pharmaceutical products. WADA: not listed on the 2026 Prohibited List. Athletes can use without WADA violation concern.
BPC-157 has neurotrophic and angiogenic properties in neural tissue (dopaminergic system repair, vagal pathway modulation). TB-500 promotes cellular migration and tissue repair. Combining these healing peptides with Cerebrolysin's neurotrophic factor mimicry is mechanistically non-redundant: Cerebrolysin provides the neurotrophic growth signals; BPC-157 supports dopaminergic integrity and tissue repair; TB-500 supports vascular and cellular regeneration. This combination is used in the community for post-TBI recovery and general CNS restoration. No controlled study of this combination exists.
GHK-Cu upregulates BDNF through TrkB sensitization and anti-inflammatory mechanisms. Cerebrolysin provides exogenous BDNF-mimicking peptide fragments. Both compounds work toward BDNF-mediated neuroplasticity through different mechanisms — GHK-Cu through endogenous BDNF upregulation; Cerebrolysin through direct neurotrophic factor mimicry. Mechanistically non-redundant. Used together in some community neuroplasticity protocols.
Semax also upregulates BDNF (Dolotov 2006) and activates MC4R/catecholamine pathways. Selank has anxiolytic-nootropic effects through GABAergic and enkephalin pathways. Community users — particularly those familiar with Eastern European pharmaceutical traditions — frequently combine Cerebrolysin with Semax (for the cognitive/BDNF effects) and sometimes Selank (for the anxiolytic balance). This is the 'Russian nootropic stack' — all three are approved pharmaceuticals in Russia/Eastern Europe, and combining them has a long community history. The combination is mechanistically coherent and mechanistically distinct at each component's receptor level. No controlled study.
Neural recovery and neuroplasticity are energetically demanding processes. NAD+ supports the mitochondrial function and DNA repair that underlie cellular resilience and neuroplasticity. Combining Cerebrolysin (neurotrophic signaling) with NAD+ precursors (cellular energy and DNA repair support) addresses the signaling and the energetic requirements of neural repair simultaneously. Mechanistically non-redundant. Low interaction risk.
Activation effects: increased mental energy, alertness, slight social disinhibition reported by some users. Occasionally mild headache or dizziness. Some users report no perceptible effect in the first days.
Peak reported cognitive effects: improved verbal fluency, faster information processing, enhanced memory consolidation, mood brightening. The most consistently reported benefit window in community experience.
'Afterglow' period: many community users report cognitive effects persisting 2-4 weeks after cycle completion. Consistent with the neurotrophic factor hypothesis — neuroplasticity changes induced during the cycle may persist beyond peptide clearance.
Community experience with Cerebrolysin is more developed than for many compounds in this book, given its long history of use in Eastern European and Russian clinical medicine and its substantial biohacker following. Reported timelines:
Timeframe
Community-Reported (Grade E)
Clinical Trial Context
Days 1-3
Activation effects: increased mental energy, alertness, slight social disinhibition reported by some users. Occasionally mild headache or dizziness. Some users report no perceptible effect in the first days.
Clinical trials: NIHSS improvements start appearing at day 5-7 in stroke trials; no specific early-phase cognitive report in clinical data
Days 4-10
Peak reported cognitive effects: improved verbal fluency, faster information processing, enhanced memory consolidation, mood brightening. The most consistently reported benefit window in community experience.
Clinical trials: NIHSS and cognitive scale improvements typically assessed at day 10 (end of standard course)
Post-cycle (weeks 1-4)
'Afterglow' period: many community users report cognitive effects persisting 2-4 weeks after cycle completion. Consistent with the neurotrophic factor hypothesis — neuroplasticity changes induced during the cycle may persist beyond peptide clearance.
Clinical trials: follow-up at 90 days shows sustained benefit in some trials — consistent with neuroplasticity persistence beyond acute treatment
Based on the clinical trial evidence, Cerebrolysin is most pharmacologically rational for: post-stroke recovery (used in appropriate clinical setting, ideally IV); post-TBI cognitive recovery; individuals with cognitive decline associated with vascular dementia or Alzheimer's disease (with physician oversight). For healthy adults seeking cognitive enhancement: the evidence is absent. There is mechanistic coherence to the hypothesis that neurotrophic factor mimicry could support neuroplasticity in healthy adults — but no clinical data validates it. The community uses it extensively for this purpose. The honest assessment: healthy adult nootropic use is an extrapolation from clinical pathology data. That extrapolation may or may not be valid; we do not know.
Community users who use SubQ or IM injection rather than IV are operating outside the evidence base entirely in terms of pharmacokinetics. The practical implications: some neuropeptide bioavailability will be achieved through SubQ/IM — this route is not pharmacologically zero. But whether it produces 20%, 50%, or 80% of IV bioavailability for the relevant peptide fractions is unknown. Community experience suggests the SubQ/IM route produces perceptible effects — consistent with some systemic exposure. Whether that exposure is therapeutically equivalent to the clinical trial IV doses is a different question.
The clinical trial precedent: courses of 10-20 days. Community standard: 10 days on, 4-8 weeks off before next course. The rationale: neurotrophic factor signaling likely produces its structural changes (synaptic remodeling, neuroplasticity) during the active course; the break period allows assessment and washout; repeated cycles may build on previous neuroplastic changes. No specific cycling protocol is validated for community use — the clinical trials did not test repeated courses in most cases.
The honest position on Cerebrolysin in 2026: a compound with five decades of clinical use, approval in over 40 countries, and an evidence base that modern independent review consistently rates as insufficient for confident clinical recommendation. The mechanistic case is coherent. The community experience is substantial and largely positive. The independent scientific community's assessment — led by Cochrane — is that the trial evidence does not meet current standards for clinical confidence. These positions will not resolve until an independent, large-scale, properly conducted trial replicates the positive findings claimed in industry-affiliated literature.
Research provenance note: The Cerebrolysin literature is the most commercially concentrated in this book. Every trial citation requires checking the authorship disclosures. The pattern: EVER Neuro Pharma (formerly EBEWE Pharma) affiliated researchers generate most of the positive literature; independent investigators generate the negative evidence. This is documented in the citations below.
Heiss WD, Brainin M, Bornstein NM, Tuomilehto J, Hong Z; CASTA Investigators. (2012). Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 43(3):630-636. doi:10.1161/STROKEAHA.111.628537. [n=1,070; INDEPENDENT; acute ischemic stroke; 30 mL Cerebrolysin IV x 10 days; PRIMARY ENDPOINT FAILED — combined global directional test NS; post-hoc mortality signal in severe stroke subgroup (10.5% vs 20.2%); the most important single trial in the Cerebrolysin evidence base]
Patel PN, Mangal D, Patel K. (2025). Safety and Efficacy of Cerebrolysin for Neurorecovery After Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of 14 Randomized Controlled Trials. Cureus. PMC12465088. [14 RCTs, n=2,884; NIHSS improvement MD +1.39 (p=0.020); functional independence (mRS 0-2): non-significant; GRADE: low certainty; predominantly industry-affiliated trials included; Cochrane 2023 cited as additional context]
Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. (2023). Cerebrolysin for acute ischaemic stroke. Cochrane Database of Systematic Reviews. 2023:CD007026. doi:10.1002/14651858.CD007026.pub7. [INDEPENDENT Cochrane review — most methodologically rigorous assessment of the stroke literature; conclusion: low to very low certainty evidence; does not establish sufficient basis for routine clinical recommendation; the most important independent evidence assessment]
Guekht A, Vester J, Heiss WD, et al. (2017) [4]. Safety and efficacy of Cerebrolysin in motor function recovery after stroke: a meta-analysis of the CARS trials. Neurological Sciences. 38(8):1443-1450. doi:10.1007/s10072-017-3037-z. [EVER Neuro Pharma affiliated authors including Stefan Winter (EVER Neuro Pharma employee) and Dafin Muresanu (received EVER Neuro Pharma grants); CARS-1 and CARS-2 meta-analysis; positive motor recovery findings — read with commercial provenance awareness]
Rejdak K, Sienkiewicz-Jarosz H, Bienkowski P, Alvarez A. (2023) [5]. Modulation of neurotrophic factors in the treatment of dementia, stroke and TBI: Effects of Cerebrolysin. Medicinal Research Reviews. 43(4):1668-1700. doi:10.1002/med.21960. [Note: 'Several authors of that review have declared ties to EVER Neuro Pharma' — acknowledged in independent assessments; comprehensive mechanism review; BDNF, NGF, IGF-1, VEGF, TNF-alpha modulation documented across preclinical and clinical studies; read with commercial provenance awareness]
[Title: 'Hope Dies Last — Evidence Again Fails to Support a Neuroprotectant'] Stroke. 2017;48. [Editorial responding to CASTA and ongoing Cerebrolysin controversy; the title encapsulates the independent clinical neurology community's perspective on this literature]
European Academy of Neurology / European Federation of Neurorehabilitation Societies. (2021). Guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke. Eur J Neurol. 28(9):2831-2845. doi:10.1111/ene.14936. [Weak recommendation for Cerebrolysin in motor rehabilitation context; reflects the regulatory reality that approved pharmaceuticals can receive guideline recommendations despite Cochrane-level evidence uncertainty]
Cerebrolysin is the most clinically tested compound in this book and the most evidence-contested. Five decades of data have not produced scientific consensus. Understanding why requires understanding the commercial provenance of that data.
The central tension resolved: Cerebrolysin has been studied in more human clinical trials than any other compound in this book. It is approved in over 40 countries. It appears in European neurology guidelines. Its mechanistic rationale — neurotrophic factor mimicry via BDNF, NGF, GDNF, and CNTF-homologous peptide fragments — is biologically coherent and supported by extensive preclinical evidence. And: the Cochrane systematic review — the gold standard of independent evidence assessment — has rated the evidence as 'low to very low certainty' across all its updates. The largest independent RCT (CASTA, n=1,070) failed its primary endpoint. A journal editorial titled 'Hope Dies Last' summarized the clinical neurology community's frustration with decades of inconsistent results. The pattern in the literature — positive trials concentrated among industry-affiliated researchers, negative results from independent investigators — is the most important interpretive context and the most underappreciated fact in community discourse about Cerebrolysin.
The community uses Cerebrolysin primarily for an indication (cognitive enhancement in healthy neurologically normal adults) for which there is no clinical trial evidence at all. Every positive trial enrolled patients with acute stroke, TBI, or dementia. The extrapolation from 'it helps injured or demented brains recover' to 'it enhances healthy brain performance' may be biologically reasonable but it is clinically unvalidated. The route issue compounds this: clinical trials used 30 mL IV infusion; the community uses 1-5 mL SubQ or IM. Whether community-equivalent doses by community-equivalent routes produce pharmacologically meaningful exposure is unknown.
The argument for Cerebrolysin: there is more human data than for many compounds in this book. The compound has been used clinically for five decades without a serious safety signal. Community experience is largely consistent with the positive trial findings — subjectively reported cognitive improvement during and after a course. Some positive independent replication does exist at the individual trial level even if Cochrane finds the aggregate uncertain. The compound is a pharmaceutical-grade product (when sourced from EVER Neuro Pharma) with GMP manufacturing quality. The neurotrophic factor mechanism is compelling biologically.
The argument for caution: the positive trial data is commercially concentrated. The independent evidence is negative (CASTA) or insufficient (Cochrane). The community uses it at doses, by routes, and for indications that have no validated evidence. The composition is incompletely characterized. Sourcing from research vendors rather than pharmaceutical-grade imports removes the quality assurance that distinguishes the clinical trial product from the research chemical market.
Cerebrolysin is the most clinically tested compound in this book and the most evidence-contested. Five decades of data have not produced scientific consensus. Understanding why requires understanding the commercial provenance of that data.
The central tension resolved: Cerebrolysin has been studied in more human clinical trials than any other compound in this book. It is approved in over 40 countries. It appears in European neurology guidelines. Its mechanistic rationale — neurotrophic factor mimicry via BDNF, NGF, GDNF, and CNTF-homologous peptide fragments — is biologically coherent and supported by extensive preclinical evidence. And: the Cochrane systematic review — the gold standard of independent evidence assessment — has rated the evidence as 'low to very low certainty' across all its updates. The largest independent RCT (CASTA, n=1,070) failed its primary endpoint. A journal editorial titled 'Hope Dies Last' summarized the clinical neurology community's frustration with decades of inconsistent results. The pattern in the literature — positive trials concentrated among industry-affiliated researchers, negative results from independent investigators — is the most important interpretive context and the most underappreciated fact in community discourse about Cerebrolysin.
The community uses Cerebrolysin primarily for an indication (cognitive enhancement in healthy neurologically normal adults) for which there is no clinical trial evidence at all. Every positive trial enrolled patients with acute stroke, TBI, or dementia. The extrapolation from 'it helps injured or demented brains recover' to 'it enhances healthy brain performance' may be biologically reasonable but it is clinically unvalidated. The route issue compounds this: clinical trials used 30 mL IV infusion; the community uses 1-5 mL SubQ or IM. Whether community-equivalent doses by community-equivalent routes produce pharmacologically meaningful exposure is unknown.
The argument for Cerebrolysin: there is more human data than for many compounds in this book. The compound has been used clinically for five decades without a serious safety signal. Community experience is largely consistent with the positive trial findings — subjectively reported cognitive improvement during and after a course. Some positive independent replication does exist at the individual trial level even if Cochrane finds the aggregate uncertain. The compound is a pharmaceutical-grade product (when sourced from EVER Neuro Pharma) with GMP manufacturing quality. The neurotrophic factor mechanism is compelling biologically.
The argument for caution: the positive trial data is commercially concentrated. The independent evidence is negative (CASTA) or insufficient (Cochrane). The community uses it at doses, by routes, and for indications that have no validated evidence. The composition is incompletely characterized. Sourcing from research vendors rather than pharmaceutical-grade imports removes the quality assurance that distinguishes the clinical trial product from the research chemical market.
Compound
Human RCT Data
Cochrane Status
Commercial Provenance
Community Use Aligned with Evidence?
Cerebrolysin
Extensive (dozens of RCTs)
Low to very low certainty
Heavily EVER Neuro Pharma concentrated
No — healthy adult cognitive use; SubQ route; lower doses
Retatrutide
Phase 3 (TRIUMPH-4)
Not Cochrane-reviewed; Phase 3 quality
Eli Lilly (disclosed); large academic trials
Partial — community uses but off-label and pre-approval
SS-31 (Elamipretide)
Phase 2/3; FDA approved (Barth)
Not Cochrane-reviewed
Academic + Stealth BioTherapeutics (disclosed)
Partial — community uses off-label
BPC-157
Zero human RCTs
Not reviewed — no data
Croatian single-lab primary
No — entirely preclinical extrapolation
Semax
Russian pharmaceutical approval
Not reviewed — non-Western
Russian Institute of Molecular Genetics
Partial — approved in Russia; Western use off-label
— End of Cerebrolysin —
THE PEPTIDE BIBLE | Cerebrolysin | For Research & Educational Purposes Only
Cerebrolysin is a biological extract — not a single defined compound — produced by enzymatic hydrolysis of porcine brain cortex. Composition: approximately 25% low-molecular-weight peptides (MW <10,000 Da, most 1,000-3,000 Da) and 75% free amino acids. Specific peptide content not fully characterized publicly; fragments with BDNF, NGF, GDNF, CNTF, and IGF-1 homology proposed as active components. Manufacturer: EVER Neuro Pharma GmbH (Austria). Approved pharmaceutical in 40+ countries including Russia, China, Eastern Europe, South Korea. NOT FDA approved. NOT EMA approved EU-wide. WADA: not listed. Mechanism: neurotrophic factor mimicry — proposed TrkB (BDNF-like), TrkA (NGF-like), CNTFR (CNTF-like) receptor activation → neuronal survival (anti-apoptotic), synaptic plasticity, neurogenesis, M1→M2 microglial shift (anti-inflammatory). BBB penetration proposed for low-MW fractions but not directly characterized in humans. Route: pharmaceutical-grade IV infusion 30-50 mL/day (clinical trial protocol); community uses SubQ/IM 1-5 mL/day. ORAL ROUTE DOES NOT WORK — GI peptide degradation. Clinical evidence: dozens of RCTs spanning stroke, TBI, Alzheimer's disease, vascular dementia. KEY FINDING — commercial provenance: positive trials predominantly have EVER Neuro Pharma authors/funding; independent trials are negative or neutral. CASTA trial (Stroke, 2012, n=1,070, INDEPENDENT): PRIMARY ENDPOINT FAILED for acute ischemic stroke. 2025 meta-analysis (14 RCTs, n=2,884): NIHSS improvement MD +1.39 (significant) but functional independence non-significant; GRADE: low certainty. Cochrane 2023 (INDEPENDENT): 'low to very low certainty' — does not support routine clinical recommendation. European Academy of Neurology: weak recommendation for motor rehabilitation. Healthy adult cognition: ZERO clinical trial evidence. SubQ/IM route equivalence to IV: UNTESTED ASSUMPTION. Safety: generally favorable in clinical literature; injection site reactions most common; rare hypersensitivity; porcine origin (pork allergy contraindication); avoid in epilepsy (relative). The central tension: five decades of clinical use, approval in 40+ countries, dozens of RCTs — and Cochrane rates it 'low to very low certainty,' the largest independent trial failed, and the commercial provenance of the positive evidence is the most concentrated in this book.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.